| Literature DB >> 30627331 |
Umut Safiye Say Coskun1, Aysegul Copur Cicek2, Cetin Kilinc3, Ridvan Guckan3, Yelda Dagcioglu4, Osman Demir5, Cemal Sandalli2.
Abstract
Background: A toxin-antitoxin (TA) system is a set of two or more closely linked genes that are encoded as a poison and a corresponding antidote on a protein. In typical bacterial physiology, an antitoxin binds to a toxin and neutralizes it, which prevents the bacterium from killing itself. We aimed to determine whether P.aeruginosa and Staphylococcus isolates have TA genes and to investigate whether there is a relationship between the expression levels of TA genes and resistance to antibiotics.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30627331 PMCID: PMC6307074 DOI: 10.4314/mmj.v30i2.3
Source DB: PubMed Journal: Malawi Med J ISSN: 1995-7262 Impact factor: 0.875
Primers used for detection of TA genes and analysis of real time PCR in P. aeruginosa and Staphylococus clinical isolates
| Primer name | 5′-3′ Sequence | Expected Fragment, bp | Application Reference |
| F-ATCATCGGATAAGTACGTCAGTTT | 408 | ||
| R-AGAAGGATATTCACAAATGCTGA | |||
| relBE | |||
| F-CAGGGGGTAATTTCGACTCTG | 505 | ||
| R-ATGAGCACCGTAGTCTCGTTC | |||
| higBA | |||
| F-CTCATGTTCGATCTGCTTGC | 469 |
Figure 1Multiplex PCR images of P. aeruginosa relBE and higBa TA genes
Distribution of clinical specimens of P. aeruginosa and Staphylococcus isolates
| Microorganism | ||
| 34 / 37 | 4 / 8.3 | |
| 23 / 25 | 87 / 58.8 | |
| 10 / 10.8 | 24 / 16.2 | |
| 9 / 9.7 | - | |
| 5 / 5.4 | - | |
| 4 / 4.3 | 1 / 0.7 | |
| 3 / 3.3 | 6 / 4 | |
| 3 / 3,3 | 3 / 2 | |
| 1 / 1.1 | - | |
| - | 1 / 0.7 | |
| - | 1 / 0.7 | |
| - | 6 / 4 | |
| - | 15 / 10.1 |
Antibiotic resistance rates of P. aeruginosa and Staphylococcus isolates
| Staphylococcus isolates | |||
| Antibiotic | n / % | Antibiotic | n / % |
| Meropenem | 59 / 67 | Penicillin | 126 / 95.5 |
| Imipenem | 52 / 59.8 | Sefoksitin | 84 / 63.6 |
| Cefoperazone-sulbactam | 36 / 42.9 | Gentamicin | 36 / 27.3 |
| Ceftazidime | 20 / 23.8 | Erythromycin | 101 / 7.6 |
| Piperacillin-tazobactam | 19 / 21.8 | Clindamycin | 41 / 31 |
| Ciprofloxacin | 19 / 21.8 | Linezolid | 0 |
| Cefepime | 14 / 15.9 | Daptomycin | 0 |
| Aztreonam | 12 / 13.6 | Teicoplanin | 0 |
| Vancomycin | 0 | ||
| Ciprofloxacin | 44/33.3 | ||
| Levofloxacin | 31/23.5 | ||
| Tetracycline | 45/34 | ||
| Fusidic acid | 35/26.5 | ||
| Trimethoprim-sulfamethoxazole | 22/16.6 | ||
Antibiotic resistance status and mazEF cT values of Staphylococcus isolates
| Factors | MazEF Ct Values | p | ||
| Mean±SD | ||||
| Group | MSSA | 48 | 23.3±5.42 | <0.001 |
| Penicillin | Sensitive | 6 | 25.9±6.24 | 0.751* |
| Resistant | 126 | 24.68±6.94 | ||
| Gentamicin | Sensitive | 96 | 23.98±6.44 | 0.038 |
| Resistant | 36 | 26.76±7.7 | ||
| Ciprofloxacin | Sensitive | 88 | 23.51±6.14 | 0.007 |
| Resistant | 44 | 27.19±7.68 | ||
| Levofloxacin | Sensitive | 101 | 23.82±6.35 | 0.015 |
| Resistant | 31 | 27.71±7.81 | ||
| Erythromycin | Sensitive | 31 | 22.81±6.88 | 0.074 |
| Resistant | 101 | 25.33±6.82 | ||
| Clindamycin | Sensitive | 91 | 23.75±6.69 | 0.013 |
| Resistant | 41 | 26.93±6.9 | ||
| Linezolid | Sensitive | 132 | 24.67±6.87 | - |
| Resistant | 0 | |||
| Daptomycin | Sensitive | 132 | 24.74±6.89 | - |
| Resistant | 0 | - | ||
| Teicoplanin | Sensitive | 132 | 24.73±6.92 | - |
| Resistant | 0 | |||
| Vancomycin | Sensitive | 132 | 24.73±6.92 | - |
| Resistant | 0 | |||
| Tetracycline | Sensitive | 87 | 24.63±7.12 | 0.807 |
| Resistant | 45 | 24.94±6.48 | ||
| Fusidic acid | Sensitive | 97 | 23.81±6.42 | 0.010 |
| Resistant | 35 | 27.3±7.56 | ||
| Trimethoprim-sulfamethoxazole | Sensitive | 110 | 24.86±6.86 | 0.662 |
| Resistant | 22 | 24.15±7.15 | ||
| Cefoxitin | Sensitive | 48 | 23.3±5.42 | 0.048 |
| Resistant | 84 | 25.56±7.51 | ||
| Inducible | Sensitive | 87 | 25.57±6.15 | 0.002* |
MSSA: Methicillin-sensitive Staphylococcus aureus; MRSA: Methicillin-resistant S. aureus; CNS: Coagulase negative staphylococcus,
Figure 2The distribution of MazEF values by groups in Staphylococcus isolates